• Cambridge Research & Instrumentation (CRi; Woburn, Massachusetts) is shipping DyCE (dynamic contrast enhancement), a new technology application, to users of the Maestro in vivo molecular imaging system. Customers can now generate all-optical anatomical images of mouse models in a few minutes, saving time and enabling better time-resolved images of molecular probe distribution. Anatomical images are produced using DyCE in the following way. A bolus of an inert near-infrared dye (such as indocyanine green) is injected, and then a time-based series of data is collected. Using CRi's analysis software, this data set is interpreted to delineate most of the major organ systems, using optical imaging alone. This organ-specific imaging is possible, because organs have characteristic uptake or distribution patterns over time that can be 'illuminated' by the dye passing through, distinguishing them from other structures. CRi makes optical imaging products.

• CryoLife (Kennesaw, Georgia) reported implantation of the first CryoValve SG pulmonary human heart valve since the product was cleared by the FDA. The procedure was performed on a patient at St. Louis Children's Hospital (St. Louis). The CryoValve SG is processed with the company's SynerGraft technology, which removes allogeneic donor cells and cellular remnants from the valve without compromising the integrity of the underlying collagen matrix. The CryoValve SG is indicated for the replacement of diseased, damaged, malformed or malfunctioning native pulmonary valves in pediatric and adult patients. The valve can be used in conjunction with right ventricular outflow tract reconstruction procedures, commonly performed in children with congenital heart defects. In addition, the valve can be used for pulmonary valve replacement during the Ross Procedure, an operation in which a patient's defective aortic valve is removed and replaced with his own pulmonary valve. The CryoValve SG is then surgically implanted in place of the removed native pulmonary valve. CryoLife is a biomaterials, medical device and tissue processing company.

• LDR (Austin, Texas) reported enrollment completion for the two-level IDE study on its second-generation Mobi-C cervical artificial disc. The Mobi-C mobile bearing design reduces the stresses on the bone, thereby eliminating the need for invasive screws or keels. These features make the Mobi-C ideal for multi-level surgeries, an anticipated indication for many patients throughout the world. LDR was created to bring innovative non-fusion and fusion spine implants that address unmet or underserved needs to market. The company is now selling its products worldwide in more than 30 countries. LDR is a privately held company developing spinal implants for both non-fusion and fusion applications.